基因治疗相关葡萄膜炎(GTAU):认识与减轻视网膜基因治疗中的不良免疫反应
视网膜基因治疗使用腺相关病毒(AAV)载体治疗遗传性视网膜疾病,但载体的先天性和适应性免疫反应可导致基因治疗相关葡萄膜炎(GTAU),可能引起视网膜细胞不可逆丢失、视功能恶化和疗效持久性降低。本文汇总临床前研究、临床试验和真实世界实施经验,提出GTAU风险框架包括患者人口学、载体构建、载体剂量、给药途径和免疫抑制方案选择,并倡导基于更好理解免疫反应基础的更靶向免疫调节方法。
要点
- GTAU由针对AAV载体组分的先天性和适应性免疫反应引起,可致视网膜细胞不可逆丢失和视功能恶化。
- GTAU风险框架包括患者人口学、载体构建、载体剂量、给药途径和免疫抑制方案选择。
- 作者倡导基于更好理解免疫反应基础的更靶向免疫调节方法预防和治疗GTAU。
核心结论
- 为使视网膜基因治疗在更多遗传性视网膜疾病和更常见疾病中实现更好的疗效和安全性,必须最小化GTAU风险。
- 作者倡导基于更好理解免疫反应基础的更靶向免疫调节方法预防和治疗GTAU。
研究设计与样本
- 本文汇总临床前研究、临床试验和AAV介导视网膜基因治疗真实世界实施的经验与见解。
主要发现
- 眼内针对载体产品组分的先天性和适应性免疫反应限制治疗性转基因的递送和表达,称为基因治疗相关葡萄膜炎(GTAU)。
- GTAU临床重要,因为眼内炎症可导致视网膜细胞不可逆丢失、视功能恶化和与昂贵一次性治疗相关的疗效持久性降低。
- 作者提出一个新兴框架,包括患者人口学、载体构建、载体剂量、给药途径和免疫抑制方案选择。
- 作者考虑迄今在以上各领域减轻不良免疫反应的努力和潜在未来策略。
临床怎么用
- 作者倡导基于更好理解免疫反应基础的更靶向免疫调节方法预防和治疗GTAU。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Retinal gene therapy using adeno-associated viral (AAV) vectors has been a groundbreaking step-change in the treatment of inherited retinal diseases (IRDs) and could also be used to treat more common retinal diseases such as age-related macular degeneration and diabetic retinopathy. The delivery and expression of therapeutic transgenes in the eye is limited by innate and adaptive immune responses against components of the vector product, which has been termed gene therapy-associated uveitis (GTAU). This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment. For retinal gene therapy to achieve an improved efficacy and safety profile for treating additional IRDs and more common diseases, the risk of GTAU must be minimised. We have collated insights from pre-clinical research, clinical trials, and the real-world implementation of AAV-mediated retinal gene therapy to help understand the risk factors for GTAU. We draw attention to an emerging framework, which includes patient demographics, vector construct, vector dose, route of administration, and choice of immunosuppression regime. Importantly, we consider efforts to date and potential future strategies to mitigate the adverse immune response across each of these domains. We advocate for more targeted immunomodulatory approaches to the prevention and treatment of GTAU based on better understanding of the underlying immune response.
引用
- Purdy R, John M, Bray A, et al. Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy. Prog Retin Eye Res. 2025. PMID: 40090458. doi:10.1016/j.preteyeres.2025.101354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。